In Silico and In Vitro Immunomodulatory Studies on Compounds of Lindelofia stylosa

Chemical Biology and Drug Design

Volumn 79, Issue 3, 2012, Pages 290-299

  Mesaik, M Ahmed ^a   Jabeen, Almas ^a   Halim, Sobia A ^a   Begum, Afshan ^b   Khalid, A Shukralla ^a,c   Asif, Muhammad ^a   Fatima, Beenish ^a   Ul Haq, Zaheer ^a   Choudhary, M Iqbal ^a,d  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b UNIVERSITY OF HAMBURG   (Germany)

^c MINISTRY OF SCIENCE AND TECHNOLOGY   (Sudan)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

IL 2 inhibition; Immunomodulation; Lindelofia stylosa; Molecular docking; Oxidative burst; T cell proliferation

Indexed keywords

13 (3 O FERULOYL 6' O COUMAROYL NYSTOSE); 3 O FERULOYL 6' O COUMAROYL 1 KESTOSE; 3 O FERULOYL 6' O COUMAROYL SUCROSE; 3,6' O DIFERULOYL 1 KESTOSE; 3,6' O DIFERULOYL NYSTOSE; 3,6' O DIFERULOYL SUCROSE; 3O FERULOYL 6' O CAFFEOYL SUCROSE; 4' HYDROXY 5 METHOXY 6,7 METHYLENEDIOXYISOFLAV ONE; ETHYL LITHOSPERMATE; ETHYL ROSMARINATE; FERULIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; LINDELOFIA STYLOSA EXTRACT; LITHOSPERMATE B; METHYL LITHOSPERMATE; METHYL ROSMARINATE; NAPHTHALENE GLYCOSIDE (8 O BETA DEXTRO GLUCOPYRANOSIDE); PARA COUMARIC ACID; PLANT EXTRACT; REACTIVE OXYGEN METABOLITE; ROSMARINIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; LEUKEMIA CELL; LINDELOFIA STYLOSA; MEDICINAL PLANT; MOLECULAR DOCKING; PRIORITY JOURNAL; T LYMPHOCYTE;

BINDING SITES; BORAGINACEAE; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-2; NEUTROPHILS; PLANTS, MEDICINAL; PROTEIN STRUCTURE, TERTIARY; REACTIVE OXYGEN SPECIES;

LINDELOFIA;

EID: 84856039449     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01310.x     Document Type: Article

References (30)

1. Choudhary M.I., Begum A., Abbaskhan A., Ajaz A., Shafique-ur-Rehman, Atta-ur-Rahman (2005) Phenyl polypropanoids from Lindelofia stylosa. Chem Pharm Bull (Tokyo);53:1469-1471.
2. Choudhary M.I., Begum A., Abbaskhan A., Shafiq-ur-Rehman, Atta-ur-Rahman (2006) Cinnamate derivatives of fructo-oligosaccharides from Lindelofia stylosa. Carbohydr Res;341:2398-2405.
3. Choudhary M.I., Begum A., Abbaskhan A., Musharraf G., Atta-ur-Rahman (2008) Anti-oxidant phenylpropanoids and naphthalene glycoside from Lindelofia stylosa. Chem Biodiv;5:2676-2683.
4. Filippin L.I., Vercelino R., Marroni N.P., Xavier R.M. (2008) Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol;152:415-422.
5. Economides A.N., Carpenter L.R., Rudge J.S., Wong V., Koehler-Stec E.M., Hartnett C., Pyles E.A., Xu X., Daly T.J., Young M.R. (2002) Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med;9:47-52.
6. Ingegnoli F., Fantini F., Griffini S., Soldi A., Meroni P.L., Cugno M. (2010) Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol;28:254-257.
7. Nomura T., Abe Y., Kamada H., Shibata H., Kayamuro H., Inoue M., Kawara T., Arita S., Furuya T., Yamashita T. (2011) Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice. J Control Release;149:8-14.
8. Choy E.H.S., Panayi G.S. (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med;344:907-916.
9. Bertolini D.R., Nedwin G.E., Bringman T.S., Smith D.D., Mundy G.R. (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature;319:516-518.
10. Saklatvala J. (1986) Tumour necrosis factor stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature;322:47-549.
11. Chu C.Q., Field M., Feldmann M., Maini R.N. (1991) Localization of tumor necrosis factor in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum;341:125-1132.
12. Neidel J., Schulze M., Lindschau J. (1995) Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor in the knee-joints of patients with rheumatoid arthritis. Inflamm Res;44:217-221.
13. Boissier M.C. (2000) Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis;59:i103-i108.
14. Kinne R.W., Brauer R., Stuhlmuller B., Palombo-Kinne E., Burmester G.R. (2000) Macrophages in rheumatoid arthritis. Arthritis Res;2:189-202.
15. Tsai T., Hseih C., Lin Y., Tsai W., Kuo Y.C. (2001) Enhancement of cell proliferation and cytokines production in human peripheral blood mononuclear cells by extracts from blood enriching Dang-Qui decoction. J Chin Med;12:191-202.
16. Tsytsikov V.N., Yurovsky V.V., Atamas S.P., Alms W.J., White B. (1996) Identification and characterization of two alternative splice variants of human interleukin-2. J Biol Chem;271:23055-23060.
17. Yamamura M., Wang X.H., Ohmen J.D., Uyemura K., Rea T.H., Bloom B.R., Modlin R.L. (1992) Cytokine patterns of immunologically mediated tissue damage. J Immunol;149:1470-1475.
18. Mukaida N., Morita M., Ishikawa Y., Rice N., Okamoto S., Kasahara T., Matsushima K. (1994) Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem;269:13289-13295.
19. Burkhard P., Hommel U., Sanner M., Walkinshaw M.D. (1999) The discovery of steroids and other novel FKBP inhibitors using a molecular docking program. J Mol Biol;287:853-858.
20. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000) The protein data bank. Nucleic Acids Res;28:235-242.
21. Arkin M.R., Randal M., DeLano W.L., Hyde J., Luong T.N., Oslob J.D., Raphael D.R., Taylor L., Wang J., McDowell R.S. (2003) Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci USA;100:1603-1608.
22. Thanos C.D., Randal M., Wells J.A. (2003) Potent small-molecule binding to a dynamic hot spot on IL-2. J Am Chem Soc;125:15280-15281.
23. Clark M., Cramer Iii R.D., Van Opdenbosch N. (1989) Validation of the general purpose Tripos 5.2 force field. J Comput Chem;10:982-1012.
24. Jones G., Willett P., Glen R.C., Leach A.R., Taylor R. (1997) Development and validation of a genetic algorithm for flexible docking1. J Mol Biol;267:727-748.
25. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. (2004) UCSF Chimera-A visualization system for exploratory research and analysis. J Comput Chem;25:1605-1612.
26. Sehirli Ö., Tozan A., Omurtag G.Z., Cetinel S., Contuk G., Gedik N., Sener G. (2008) Protective effect of resveratrol against naphthalene-induced oxidative stress in mice. Ecotoxicol Environ Saf;71:301-308.
27. Clement-Kruzel S., Hwang S.A., Kruzel M.C., Dasgupta A., Actor J.K. (2008) Immune modulation of macrophage pro-inflammatory response by goldenseal and Astragalus extracts. J Med Food;11:493-498.
28. Nelson B.H., Willerford D.M. (1998) Biology of the interleukin-2 receptor, Adv Immunol;70:1-81.
29. Yoon Y.D., Kang J.S., Han S.B., Park S.K., Lee H.S., Kang J.S., Kim H.M. (2004) Activation of mitogen-activated protein kinases and AP-1 by polysaccharide isolated from the radix of Platycodon grandiflorum in RAW 264.7 cells. Int Immunopharmcol;4:1477-1487.
30. Westra J., Doornbos-van der Meer B., de Boer P., van Leeuwen M.A., van Rijswijk M.H., Limburg P.C. (2004) Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. Arthritis Res Ther;6:R384-R392.